BOSTON (PRWEB) DECEMBER 31, 2019
NanoFUSE Biologics is pleased to announce the addition of Dr. Darren Lebl to its Scientific Advisory Board. NanoFUSE Biologics offers a biologically enhanced synthetic therapeutic, which is the only FDA-cleared bioactive glass and demineralized bone matrix (DBM) combined medical device.
President of NanoFUSE Biologics, Jake Lubinski, said, “We’re fortunate to have a NanoFUSE Scientific Advisory Board of the best spine and orthopedic surgeons who are at the forefront of biologics use. Dr. Lebl brings a wealth of prestigious and extensive experience with biologics and how those biologics are used to best care for patients. We are privileged to welcome Dr. Lebl as the latest member to our team.”
Dr Lebl noted, “I am honored to be part of the Scientific Advisory Board for NanoFUSE. Spine surgery continues to evolve toward less invasive techniques that require surgeons to have the latest in biologic technology like NanoFUSE to help us achieve fusion with consistently successful results”
Dr. Darren Lebl is an Associate Professor of spinal surgery specializing in minimally invasive surgery, the cervical spine, motion preserving spine procedures, and robotic computer guided navigation surgery. His practice at Hospital for Special Surgery in New York City involves a customized approach to each individual patient to help maximize quality of life and musculoskeletal health. He incorporates innovative procedures, newer and less invasive surgical techniques, and biologics into his practice
After obtaining a triple major in biochemistry & molecular biology, chemistry, and economics at The University of Chicago Dr. Lebl received his MD degree from Stanford. He completed his orthopedic residency at Harvard, a spine surgery fellowship at The Hospital for Special Surgery in New York City, and an MBA from Wharton. He pursued additional advanced spine surgery training in cervical spine disorders, occipitocervical disorders, and spinal deformity surgery with international leaders in the USA, China, Japan, Spain, and Germany.
About NanoFUSE Biologics
NanoFUSE is a biologically enhanced synthetic therapeutic that combines osteoinductive DBM with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in general orthopedic applications. NanoFUSE Biologics is a KICVentures portfolio company and is distributed by SpineFrontier.
KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE and SpineFrontier. It has headquarters in Boston, MA.
About Dr Darren Lebl
Dr. Lebl was the Editor-in-Chief of the Orthopedic Journal at Harvard Medical School and Academic Chief Resident at the Massachusetts General Hospital. He was later recognized as an “emerging leader” by the world’s oldest and most distinguished orthopedic association, the American Orthopedic Association, for his contributions to education and research. He has authored numerous peer-reviewed articles and book chapters on complication avoidance in spinal surgery, cervical spine disorders, minimally invasive procedures, and motion preserving spine procedures. Dr. Lebl was the director of both the Complex Cervical Spine Symposium and the Cervical Spine Motion Preservation Symposium at HSS. Dr. Lebl is a Fellow of the American Academy of Orthopedic Surgeons and an active member of distinguished societies such as the Cervical Spine Research Society, the North American Spine Society, and the Scoliosis Research Society.